No VCs, no problem: Building oNKo-innate into a immuno-oncology innovator

For our first episode, we’re sitting down with a founder from down under, Jai Rautela, PhD, from oNKo-innate in Melbourne, Australia. oNKo-innate’s mission is to discover and develop the most effective strategies for enhancing the natural killer cell response to cancer, which led them to develop their unique screening technology - all while intentionally not taking on VC funding.
Hear Jai talk about:
  • How Jai broke down barriers between academia and entrepreneurship to blaze a path for future biotech founders

  • oNKo-innate’s approach to building a team of academics into a successful immuno-oncology innovation company

  • Jai's experiences building a company without VC support and how that influenced oNKo-innate’s funding and partnerships strategy

Watch now


Jai Rautela
Co-founder & CEO oNKo-innate at oNKo-innate

Having earned his Ph.D from University of Melbourne in immunotherapy and breast cancer. Dr. Jai Rautela defined his mission at oNKo-Innate as curator and supporter of one the highest performing biotech teams out there with the goal of delivering curative cancer therapies for all patients.

See Benchling in action

Helix Image